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Abstract
Background: Ghrelin is a 28 amino acid peptide hormone that is expressed in the stomach and a range of
peripheral tissues, where it frequently acts as an autocrine/paracrine growth factor. Ghrelin is modified by a unique
acylation required for it to activate its cognate receptor, the growth hormone secretagogue receptor (GHSR), which
mediates many of the actions of ghrelin. Recently, the enzyme responsible for adding the fatty acid residue
(octanoyl/acyl group) to the third amino acid of ghrelin, GOAT (ghrelin O-acyltransferase), was identified.
Methods: We used cell culture, quantitative real-time reverse transcription (RT)-PCR and immunohistochemistry to
demonstrate the expression of GOAT in prostate cancer cell lines and tissues from patients. Real-time RT-PCR was
used to demonstrate the expression of prohormone convertase (PC)1/3, PC2 and furin in prostate cancer cell lines.
Prostate-derived cell lines were treated with ghrelin and desacyl ghrelin and the effect on GOAT expression was
measured using quantitative RT-PCR.
Results: We have demonstrated that GOAT mRNA and protein are expressed in the normal prostate and human
prostate cancer tissue samples. The RWPE-1 and RWPE-2 normal prostate-derived cell lines and the LNCaP, DU145,
and PC3 prostate cancer cell lines express GOAT and at least one other enzyme that is necessary to produce mature,
acylated ghrelin from proghrelin (PC1/3, PC2 or furin). Finally, ghrelin, but not desacyl ghrelin (unacylated ghrelin), can
directly regulate the expression of GOAT in the RWPE-1 normal prostate derived cell line and the PC3 prostate cancer
cell line. Ghrelin treatment (100nM) for 6 hours significantly decreased GOAT mRNA expression two-fold (P < 0.05) in
the PC3 prostate cancer cell line, however, ghrelin did not regulate GOAT expression in the DU145 and LNCaP
prostate cancer cell lines.
Conclusions: This study demonstrates that GOAT is expressed in prostate cancer specimens and cell lines. Ghrelin
regulates GOAT expression, however, this is likely to be cell-type specific. The expression of GOAT in prostate cancer
supports the hypothesis that the ghrelin axis has autocrine/paracrine roles. We propose that the RWPE-1 prostate cell
line and the PC3 prostate cancer cell line may be useful for investigating GOAT regulation and function.
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Background
Ghrelin is a 28 amino acid peptide, which is post-
translationally cleaved by furin-like proteases from a
larger (117 amino acid) preproghrelin protein [1,2].
Following cleavage of the signal peptide, proghrelin
can be post-translationally octanoylated by the enzyme
ghrelin O-acyltransferase (GOAT) at the third residue of
mature ghrelin, a serine, to form acylated ghrelin [3,4].
Proghrelin is cleaved by one of a number of enzymes,
including prohormone convertase (PC) 1/3, PC2 or furin
[1,5] to produce the 28 amino acid mature ghrelin peptide.
Ghrelin acylation is required for it to bind and activate the
classical ghrelin receptor, the growth hormone secreta-
gogue receptor (GHSR1a) [2,6]. A non-octanoylated form
of ghrelin, desacyl ghrelin, (or unacylated ghrelin), circu-
lates in the blood at higher levels than octanoylated ghrelin
[7,8], but does not activate the GHSR1a. Desacyl
ghrelin and ghrelin have functions that are mediated
by an alternative ghrelin receptor that has not yet
been identified [9]. The acylated form of ghrelin
(termed ghrelin) is a multifunctional peptide hormone
that plays a role in a range of cellular processes, including
the regulation of growth hormone and insulin release,
appetite, gut motility, and metabolism and it has roles in
the immune, cardiovascular and reproductive systems [10].
Evidence is also emerging that ghrelin plays a role in
regulating cancer progression [11,12]. Ghrelin and GHSR1a
expression has been reported in a number of cancers [12]
including breast [13,14], prostate [15-20], testicular [21],
and endometrial cancer [22,23]. We have previously
demonstrated that ghrelin and GHSR1a are expressed
in prostate cancer and prostate cancer cell lines
[16,18]. Prostate cancer tissues and cell lines express
a novel ghrelin mRNA isoform, that encodes the 28
amino acid hormone, and this isoform is regulated by
insulin [19]. Prostate cancer cell lines secrete the
ghrelin peptide and exogenous ghrelin treatment
stimulates cell proliferation in prostate cancer cell
lines and this is mediated through the ERK1/2 MAPK
pathway [16,18]. It has recently been demonstrated
that a fluorescein-labelled ghrelin (1–18) probe which
binds prostate cancer tissue can be used to distinguish
between benign prostatic disease and prostate cancer, and
therefore, may be a useful diagnostic tool [20].
The recently discovered ghrelin acylation enzyme,
ghrelin O-acyltransferase (GOAT), encoded by the gene
MBOAT4 (membrane bound O-acyl transferase 4) [3,4],
is emerging as a promising diagnostic and therapeutic
target for regulating appetite and conditions related to
the ghrelin axis, such as obesity, insulin resistance
and type 2 diabetes mellitus [24]. GOAT, like ghrelin,
is produced by the stomach, and also in a range of
peripheral tissues including the normal human prostate
[25] and in breast cancer [26]. The expression of the
GOAT gene (MBOAT4) is regulated by growth factors and
hormones, including leptin [27,28], somatostatin [28] and
ghrelin itself, but not by desacyl ghrelin [28].
In this report, we extend our previous studies, dem-
onstrating the expression and function of the ghrelin
axis in prostate cancer [16,18], to demonstrate that
prostate-derived tissues and cell lines express the
necessary enzymes required to produce the 28 amino acid
acylated ghrelin, which may play a role in prostate cancer
proliferation [16,18]. Moreover, we examined the ability of
exogenous ghrelin and desacyl ghrelin to alter the
expression of GOAT mRNA in prostate-derived cell lines.
Methods
Cell culture
Cell lines were obtained from the American Type
Culture Collection (ATCC, Rockville, MD). The non-
tumourigenic RWPE-1 (ATCC CRL-11609) and the trans-
formed, tumourigenic RWPE-2 (ATCC CRL-11610) prostate
epithelium-derived cell lines were cultured in Keratinocyte
Serum Free Medium (KSFM) (Invitrogen, Carlsbad, CA)
supplemented with 50 μg/mL bovine pituitary extract
and 5 ng/mL epidermal growth factor (Invitrogen). The
PC3 (ATCC CRL-1435), DU145 (ATCC HTB-81), and
LNCaP (ATCC CRL-1740) prostate cancer cell lines were
maintained in Roswell Park Memorial Institute 1640
medium (RPMI 1640, Invitrogen) with 10% New Zealand
Cosmic Calf Serum (HyClone, South Logan, UT, USA)
supplemented with 100 U/mL penicillin G and 100 μg/mL
streptomycin (Invitrogen).
All cell lines were passaged at two to three day inter-
vals on reaching 70% confluency using either 0.25%
Trypsin/EDTA (Invitrogen) or stable Trypsin-like
Enzyme (TrypLE Express) (Invitrogen). Cell morphology
and viability was monitored by microscopic observation
and regular Mycoplasma testing was performed by PCR
(Universal Mycoplasma Detection Kit, ATCC). All general
disposable cell culture laboratory ware was from Nagle
Nunc International (Roskilde, Denmark).
Ghrelin and desacyl ghrelin treatments
RWPE-1, LNCaP, DU145, and PC3 prostate cancer
cell lines were grown in flasks and serum-starved
overnight when they reached 70% confluency. Cells
were treated with ghrelin (0, 100 and 1000nM) or
desacyl ghrelin (0, 100 and 1000nM) (Mimotopes,
Melbourne, Australia) in phenol red-free RPMI1640
media (Invitrogen), in serum free conditions for 0, 1
and 6 hours at 37°C in a humidified atmosphere
containing 5% CO2. Cells were washed twice in phos-
phate buffered saline and removed from flasks using
cell scrapers, and cell pellets were stored at −80°C for
RNA extraction.
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RNA extraction
Total RNA was harvested from cultured cells using
QIAshredder and RNeasy Plus Mini kits (QIAGEN,
Hilden, Germany) according to the manufacturer’s
instructions and stored at −80°C. RNA concentration
and purity were measured using a NanoDrop ND-1000
spectrophotometer (Thermo Fisher Scientific, Waltham,
MA). Contaminating genomic DNA was removed by
DNase I digestion (amplification grade, Invitrogen), and
1.0 μg total RNA was reverse transcribed using the
SuperArray RT2 First Strand Kit (SABiosciences,
Frederick, MD), or using SuperScript III First strand
synthesis system (Invitrogen).
Quantification of GOAT, furin, prohormone convertase
(PC) 1/3 and PC2 mRNA expression in prostate tissues
and cell lines using real-time RT-PCR
The expression of GOAT, PC1/3, PC2 and furin mRNA
was investigated in prostate cancer cell lines. Quantitative
real-time RT-PCRs were performed using the AB 7500
sequence detection system (Applied Biosystems, AB, Foster
City, CA) in a total reaction volume of 25 μl using 2 × SYBR
Green PCR Master Mix (AB). Primers for GOAT/MBOAT4
(cat. no PPH63501A), furin (FURIN PPH09618A), PC1/3
(PCSK1 PPH10136A), and PC2 (PCSK2 PPH16826E)
were purchased from SABiosciences. Expression was
normalised to 18S ribosomal RNA (forward 5′-TTCG
GAACTGAGGCCATGAT-3′ and reverse 5′-CGAAC
CTCCGACTTTCGTTCT-3′). Fold changes were quanti-
fied as 2-(ΔCt sample-ΔCt control), as described previously [29].
Statistical analysis was performed using the Student’s t-test,
with duplicate data from two independent experi-
ments, or one-way analysis of variance (ANOVA)
with Tukey’s post-hoc analysis for multiple group
analysis, with P < 0.05 considered to be statistically
significant.
Quantification of GOAT mRNA expression in prostate
tissues using real-time RT-PCR
Real-time RT-PCR was used to determine GOAT mRNA
expression levels in samples from tissues of normal
prostate and prostate cancer patients using OriGene
TissueScan qPCR Prostate Cancer cDNA panels
(panel II, OriGene, Rockville, MD). cDNA panels
were derived from eight normal tissues and a range
of tumour tissues. Quantitative real-time RT-PCR was
performed using GOAT (MBOAT4) primers as de-
scribed above. Expression levels were normalised to
β-actin (using primers supplied with the cDNA
panel). For cDNA panels, each gene was evaluated on
separate, identical array plates, which were loaded
with equal amounts of cDNA per well, as described
by the manufacturer.
Immunohistochemistry using tissues and prostate cancer
cell lines
A prostate cancer tissue microarray (TMA) was obtained
from the Cooperative Prostate Cancer Tissue Resource
(TMA 2 Gleason) with approval from the QUT Human
Research Ethics Committee. The array contains prostate
cancer tissue cores obtained from radical prostatectomy
specimens from 250 patients, with Gleason scores of 4
(3 cases), 5 (31 cases), 6 (53 cases), Gleason 7 (54 cases),
8 (52 cases), 9 (54 cases) and Gleason 10 (2 cases). The
array also included 58 high-grade prostate intraepithelial
neoplasia (HGPIN) cases, 18 cases of benign prostatic
hyperplasia (BPH), 14 non-diseased donor prostates,
as well as the LNCaP, DU145 and PC3 prostate cancer
cell lines.
Immunohistochemical staining was performed using
a polyclonal antibody to human MBOAT4/GOAT
(raised in goat) using formalin-fixed, paraffin-embedded
human prostate cancer tissue. Sections were incubated
with anti-MBOAT4/GOAT antibody (1:100) (ab99449,
Abcam, Cambridge, UK) overnight at 4°C followed by
incubation with goat HRP-polymer-linked secondary
antibody-based detection (GHP516L, BioCare Medical,
Concord, CA) according to the manufacturer’s instruc-
tions. Human stomach was used as a positive control. This
antibody was affinity purified by the manufacturer using
the peptide to which it was raised and its specificity was
tested by pre-absorbing the antibody with GOAT peptide.
Bioinformatics
Using the Human Protein Atlas, the tissue localisation
of PC1/3, PC2 and furin expression was explored in
prostate tissues [30].
Results and discussion
GOAT mRNA is expressed in human prostate and prostate
cancer tissue and in prostate cell lines
To determine if human prostate cancer tissues and
cell lines express the enzyme which acylates ghrelin,
GOAT (MBOAT4), we performed quantitative real-time
RT-PCR. GOAT was expressed in most normal and pros-
tate cancer tissues, but was not expressed at higher levels
in prostate cancer tissue compared to normal prostate
tissue specimens, regardless of cancer stage (Figure 1), or
grade (data not shown). Our findings that GOAT was not
overexpressed in prostate cancer specimens compared to
benign prostatic tissue contrasts recent findings in breast
cancer, where it has been reported that GOAT mRNA was
overexpressed in 40 high grade tumors (G3) compared to
four normal breast samples [29].
Having confirmed that GOAT/MBOAT4 mRNA is
expressed in prostate cancer, we examined its expression
in normal prostate-derived and prostate cancer-derived
cell lines. GOAT mRNA expression was significantly
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higher in the LNCaP (13.4-fold), DU145 (2.9-fold) and
PC3 (2.6-fold) prostate cancer cell lines compared to the
normal prostate-derived RWPE-1 cell line (P < 0.05)
(Figure 2A). GOAT expression in the tumourigenic,
prostate epithelial-derived cell line, RWPE-2 (which is
derived from RWPE-1 cells subjected to K-ras oncogene
transfection) [31], was not significantly different from
the RWPE-1 cell line (Figure 2).
Prohormone convertase expression in prostate-derived
cell lines
To determine if prostate cancer cell lines have the en-
zymatic machinery necessary for preproghrelin process-
ing, we screened a range of prostate cancer cell lines
using quantitative real-time RT-PCR for the protease pro-
cessing enzymes prohormone convertase (PC)1/3, PC2
and furin, which can each process proghrelin to the 28
Figure 1 Boxplot showing relative levels of GOAT/MBOAT4 mRNA expression. Expression in normal prostate tissue (denoted N) and
prostate cancer tissue (stages II to IV) performed using an OriGene TissueScan qPCR Prostate Cancer panel. Data were normalised to β-actin and
are represented as fold changes relative to expression of transcripts in a normal prostate sample (1.0). GOAT was not differentially expressed in
any group (Kruskal-Wallis test; over all p = 0.56).
Figure 2 Real-time quantitative RT-PCR assays. Assays were performed to determine the relative mRNA expression levels of (A) GOAT
(MBOAT4), (B) PC1/3 (PCSK1), (C) PC2 (PCSK2), and (D) furin (FURIN) in the RWPE-1 and RWPE-2 normal-prostate derived cell lines and the DU145,
LNCaP and PC3 prostate cancer-derived cell lines. Data are expressed relative to the RWPE-1 cell line mRNA levels (set as 1) and are presented as
means ± S.E.M. (n = 2, assays performed in duplicate) and compared by one-way ANOVA, followed by Tukey’s post-hoc analysis.* = P < 0.05 versus
the RWPE-1 cell line.
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amino acid ghrelin peptide in a mutually exclusive manner
[1]. All of the prostate cell lines tested expressed at least
one of the processing enzymes necessary to produce the
mature ghrelin peptide (Figure 2B-C). This correlates with
our previous finding that immunoreactive ghrelin is
present in the conditioned media from PC3 and LNCaP
prostate cancer cell lines [16]. The LNCaP cell line
expressed relatively low levels of furin, PC1/3 and PC2
expression, however (Figure 2B-C). PC1/3 expression in
the DU145, PC3 and LNCaP prostate cancer cell lines was
significantly lower than the RWPE-1 normal prostate
derived cell line (P < 0.05) (Figure 2B) and similarly,
no PC1/3 expression was demonstrated in the LNCaP
and DU145 cell lines in a previous study [32]. PC1/3
expression was approximately 11-fold higher in the
RWPE-2 cell line compared to the RWPE-1 cell line, from
which this cell line was derived by transformation of the
RWPE-1 cell line with v-Ki-ras [31] (Figure 2B). Increased
PC1/3 expression has been associated with androgen
withdrawal and neuroendocrine differentiation in a PC310
prostate cancer cell line mouse xenograft model [33]. PC2
was expressed in the RWPE-1, RWPE-2, and DU145 cell
lines and at lower levels in the PC3 and LNCaP cell lines
(Figure 2C). Although we have demonstrated PC2 expres-
sion in the DU145 cell line, expression of the PC2 tran-
script was reported to be absent in this cell line in a
previous study [32]. PC1/3 is moderately to strongly
expressed in the cytoplasm of 90% of prostate cancer
samples (n = 18) in the Human Protein Atlas [30]. Furin
expression has previously been demonstrated in the LNCaP
and DU145 cell lines, [32] and furin mRNA was expressed
in all of the cell lines tested in the current study. Furin
expression in the LNCaP cell line was significantly lower
than the RWPE-1 (the reference) cell line (Figure 2D).
Prohormone convertase (PC) expression has been
associated with a number of cancers, including gynaeco-
logical cancers, and lung, skin and gastric cancer [34-36]
and PCs could provide novel targets for cancer treatments.
The prohormone convertase, PACE4, has been linked with
increased prostate cancer cell proliferation and cancer
progression, and a peptide that targets PACE4 and
furin inhibits prostate cancer proliferation [32,37].
PACE4 has not been demonstrated to have a role in
processing preproghrelin, however.
Recently, we identified a novel insulin-regulated
ghrelin mRNA isoform that is expressed in prostate
cancer cell lines and in prostate cancer [38]. As prostate
cancer cell lines produce ghrelin, and exogenous ghrelin
treatment stimulates cell proliferation in prostate cancer
cell lines, we hypothesized that the ghrelin axis may play
an autocrine/paracrine role in prostate cancer [39]. Our
previous studies demonstrated that ghrelin and the
ghrelin receptor, GHSR, are expressed at the mRNA and
protein levels in prostate cancer cell lines and prostate
cancer specimens [16,38,39]. A study demonstrating that
a fluorescein-labelled ghrelin (1–18) probe binds pros-
tate cancer tissue with high specificity also demonstrated
GHSR1a expression in the PC3 and LNCaP prostate
cancer cell lines and the BPH-1 cell line [20]. The find-
ing that prostate cancer cells and tissues also express
GOAT, the enzyme required for ghrelin octanoylation,
and the prohormone convertases that are required for
ghrelin processing, provides further support for this hy-
pothesis [16,18].
Immunohistochemical staining of human prostate tissues
and cell lines
We next demonstrated that GOAT protein is expressed in
prostate cancer tissues and benign prostatic hyperplasia
(BPH) samples using immunohistochemistry (Figure 3).
GOAT immunoreactivity in prostate cancer is characterized
by heterogenous cytoplasmic staining predominantly in
prostate epithelial cells (Figure 3). Some cancers lacked
GOAT expression, however (Figure 3D). As observed using
qRT-PCR (at the mRNA level), immunohistochemical
screening of 250 prostate tissue specimens demonstrated
that GOAT protein is not differentially expressed in human
prostate cancer. There was no correlation between
GOAT expression and tumour grade and GOAT was
not differentially expressed in benign prostatic hyperplasia
compared to prostate cancer (Figure 3A, B and C). Immu-
nohistochemical staining of BPH specimens demonstrated
light cytoplasmic staining with some membrane accentu-
ation. Many of the hyperplastic cells were noted to have
sharply stained cytoplasmic granules giving a granular,
dot-like immunoreactivity (Figure 3E, F). Cytoplasmic
staining for GOAT was also present in LNCaP, DU-145
and PC3 prostate cancer cell lines (data not shown).
Ghrelin peptide hormone treatment regulates GOAT
expression in cultured prostate-derived cells
Finally, we examined whether desacyl ghrelin or acylated
ghrelin regulate GOAT mRNA expression in prostate
cancer cell lines. Treatment with 100nM (Figure 4A, G),
or 1000nM (data not shown) acylated ghrelin for 6 hours
caused a statistically significant (P < 0.05) decrease in the
expression of GOAT mRNA in the RWPE-1 normal
prostate derived and the PC3 prostate cancer cell lines
compared to untreated controls. No changes in GOAT
mRNA expression were observed 1 hour after ghrelin or
desacyl ghrelin treatment in this cell line (data not shown).
Treatment with acylated ghrelin had no effect on GOAT
mRNA expression in the DU145 and LNCaP prostate
cancer cell lines, however (Figure 4C, E). Desacyl ghrelin
treatment did not alter the expression of GOAT/MBOAT4
mRNA in the RWPE-1, DU145, LNCaP or PC3 cell lines
(Figure 4B, D, F, H).
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By downregulating GOAT expression, ghrelin would
downregulate its octanoylation, altering the balance
between acylated ghrelin and desacyl ghrelin in the
prostate. As acylated ghrelin can bind and activate
the GHSR1a (the active form of the ghrelin receptor),
but desacyl ghrelin does not activate GHSR1a, GOAT
could act as a switch in the prostate. Desacyl ghrelin
and ghrelin can have different effects in different tissues,
and changing the balance between these two forms of
ghrelin in the prostate may also alter the physiological
response. Although desacyl ghrelin is functional in a
number of systems, but does not bind the classical
ghrelin receptor, GHSR1a, it is likely to function through
the widely hypothesised alternative ghrelin receptor [12].
GOAT modifies the ability of ghrelin to stimulate ap-
petite and it is required for behaviours associated with
hedonic feeding [40]. Ghrelin and GOAT have also been
shown to play a role in protecting against hypoglycaemia
with severe caloric restriction [41,42], however, this is
currently highly controversial and has been refuted [43].
GOAT inhibitors show promise for the development of
therapeutics for improving glucose tolerance and preventing
weight gain [44]. These inhibitors could be useful in pros-
tate cancer patients and may reduce autocrine/paracrine
ghrelin-stimulated cell proliferation. GOAT inhibitors
might also be useful for improving glucose tolerance
in patients with hyperinsulinaemia and impaired glucose
tolerance which results from androgen withdrawal therapy
for advanced prostate cancer [45].
There have been few studies into the regulation of
MBOAT4, the gene encoding GOAT, however, it is clear
that it is under tight endocrine control. In contrast to
Figure 3 Representative photomicrographs of ghrelin O-acyltransferase (GOAT) immunoreactivity in prostate cancer specimens and in
benign prostatic hyperplasia (BPH). Diffuse cytoplasmic staining was detected in (A) poorly differentiated cancer specimens, (B) Gleason grade
4 + 5 and (C) Gleason grade 4+ 2. (D) No immunoreactivity was detected in some cancers (Gleason grade 3 +3) demonstrating the heterogeneity of
GOAT expression in prostate cancer. More granular dot-like staining was present in (E, F) BPH sections. Scale bars are as indicated on micrographs.
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our findings in prostate cancer cells, ghrelin treatment
upregulates GOAT expression (2-fold) in primary mouse
pituitary cells [28]. Ghrelin has no effect on GOAT mRNA
expression in cultured murine and human chondrocytes,
however [46]. Conversely, based on forced over-expression
studies in mice, it has been proposed that GOAT may
regulate the ghrelin gene at the post-transcriptional level
in vivo, although the precise mechanisms have yet to be
determined [47]. This intriguing biological regulatory
circuit warrants further studies.
Evidence is also emerging that a number of hormones
that control the growth hormone (GH) axis, or energy
metabolism, regulate GOAT mRNA expression. Growth
hormone releasing hormone (GHRH) upregulates GOAT
mRNA levels, while somatostatin (which inhibits GH
release) down-regulates GOAT [28]. The peptide hormone
leptin (which like ghrelin plays a key role in regulat-
ing energy intake and expenditure, including appetite)
increases GOAT mRNA levels in vitro and in vivo
[27,28]. Insulin down-regulates GOAT expression in the
INS-1 rat insulinoma cell line [48], but does not affect
expression of GOAT in primary mouse pituitary cells
[28]. A recent study demonstrated that testosterone
increases GOAT mRNA levels in rat gastric tissue
[49]. It would be interesting to examine whether
GOAT is regulated by androgens in cultured prostate
cancer cells in future studies.
Although ghrelin regulated GOAT expression in the
PC3 prostate cancer cell line, it did not influence GOAT
expression in the LNCaP or DU145 prostate cancer cell
lines. This is surprising, as the PC3, DU145 and LNCaP cell
lines express ghrelin and GHSR1a and ghrelin treatment
stimulates cell proliferation in these cell lines [16,18]. The
different response may be due to the fact that the three
prostate cancer cell lines treated with ghrelin are of differ-
ent metastatic origins [50]. The PC3 prostate cancer cell
line is derived from a bone metastasis, the DU145 cell line
is derived from a brain metastasis and the LNCaP prostate
Figure 4 Real-time quantitative RT-PCR analysis of GOAT gene expression in response to ghrelin and desacyl ghrelin treatments for 6
hours. GOAT mRNA expression in ghrelin treated (A) RWPE-1 normal prostate derived cell line, and the (C) DU145, (E) LNCaP and (G) PC3
prostate cancer cell lines and desacyl ghrelin-treated (B) RWPE-1, (D) DU145 and (F) LNCaP and (H) PC3 cell lines. Data is represented as means
and standard error of two technical replicates from two independent replicate experiments (n = 2). * P < 0.05 indicates values that differ
significantly (Student’s t-test) from vehicle-treated control (set at 1).
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cancer cell line is derived from a lymph node metastasis.
The PC3 and DU145 cell lines are androgen-independent,
while the LNCaP cell line is androgen dependent. The
differential response to ghrelin treatment may reflect the
different metastatic origins of these cells, and their gene
signatures may have been influenced by their in vivo micro-
environments. Ghrelin also downregulated expression of
GOAT mRNA in the RWPE-1 normal prostate derived cell
line, however. Although this cell line is derived from
normal prostate epithelium and is non-tumourigenic, it is
derived from cells which have been transfected with human
papilloma virus 18, and this may affect their behavior [31].
Conversely, the regulation of GOAT by acyl ghrelin may be
a feature of normal prostate physiology which has been lost
in the LNCaP and DU145 cell lines, but not in the PC3 cell
line. In future studies, it would be useful to dissect the
differences between ghrelin and desacyl ghrelin induced
gene expression in the PC3 and RWPE-1 cell lines by
transcriptomic or proteomic analyses. Finally, no reliable
quantitative assays for GOAT protein levels have been
reported [24]. The development of such assays will greatly
aid in probing the interplay between ghrelin, desacyl ghrelin
and GOAT.
Conclusions
This is the first study to demonstrate the expression of
GOAT/MBOAT4 mRNA in prostate cancer tissues and
cell lines, and to examine the effect of ghrelin on GOAT
expression in cultured prostate cancer cell lines. We found
that GOAT mRNA and protein is expressed at similar
levels in the normal prostate and prostate cancer tissues
(independent of their disease stage or grade). Normal
prostate and prostate-cancer derived cell lines expressed
mRNA encoding the enzymes, PC1/3, PC2 or furin, which
are necessary to cleave ghrelin from the proghrelin pre-
cursor, and GOAT, the enzyme that octanoylates ghrelin.
This study provides further evidence that ghrelin may play
an autocrine/paracrine role in prostate cancer. Finally, we
have found that ghrelin, but not desacyl ghrelin, can
directly down-regulate the expression of GOAT in the
RWPE-1 normal derived cell line and the PC3 prostate
cancer cell line, but not in the DU145 and LNCaP prostate
cancer cell lines. This suggests that the regulation of
GOAT expression may be cell-type specific. We propose
that the RWPE-1 prostate cell line and the PC3 prostate
cancer cell line may be useful model cell lines to investigate
GOAT/MBOAT4 regulation and function.
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